ArticleCureus2026
Fertility-Sparing Surgery for Ovarian Mucinous Tumors and Risk of Recurrence.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Fertility-sparing surgery (FSS) is increasingly utilized in young women with early-stage ovarian tumors; however, data specific to mucinous histology and recurrence risk remain limited. Objective The objective of this study is to evaluate oncologic outcomes and recurrence patterns following FSS in patients with mucinous ovarian tumors. Methods This retrospective study included 32 patients with histologically confirmed mucinous ovarian tumors managed with FSS at Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore, Pakistan, a tertiary care center. Clinicopathological variables, surgical details, and follow-up outcomes were analyzed. Disease-free survival (DFS) and overall survival (OS) were assessed over a median follow-up of 18 months. Results The median age was 25-26 years (range 18-40). Histologically, 20 patients (62.5%) had mucinous borderline tumors, including 12 infiltrative subtypes, while 12 (37.5%) had mucinous carcinoma. The median tumor size in infiltrative tumors was 10 cm (range 4-30 cm). Laparotomy was performed in 68.8% of cases. At 18 months, OS was 100%, and DFS was 81.2%. Recurrence occurred in 6 patients (18.8%), predominantly in mucinous carcinoma (33.3%) and infiltrative borderline tumors (16.7%). Recurrences involved the contralateral ovary and omentoperitoneal surfaces. Tumor markers, cancer antigen 125 (CA-125) and carcinoembryonic antigen (CEA), remained normal in all patients. Conclusion FSS is a safe option in selected patients with mucinous ovarian tumors, demonstrating excellent survival outcomes. However, recurrence risk is influenced by histological subtype, particularly mucinous carcinoma and infiltrative borderline tumors, necessitating careful patient selection and close follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.